Skip to content

Study · Animal study (in vivo) · mouse · 2020

9 results

The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test.

Yin X, Jing Y, Chen Q, Abbas AB, Hu J, Xu H

European journal of pharmacology8 Jan 2020Cited by 38 (Europe PMC)

PMID31926126 (opens in a new tab)DOI10.1016/j.ejphar.2020.172909 (opens in a new tab)PepBankPUB-31926126
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal MOTS‑c reduced the time spent licking the paw in phase 2 of the formalin test in a dose-dependent manner.

    In plain wordsIn mice, MOTS‑c injections reduced paw licking after formalin injection, and larger doses reduced it more.

    Peptide
    MOTS-c
    Outcome
    DecreaseLicking time in phase 2 of the formalin test
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Our results showed that the intraperitoneal administration of MOTS-c reduced the time spent on licking in phase 2 in a dose-dependent manner in the formalin test.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, the AMPK antagonist compound C attenuated the antinociceptive effect of MOTS‑c 50 mg/kg in the formalin test.

    In plain wordsIn mice, a drug that blocks AMPK weakened the pain-reducing effect of MOTS‑c.

    Peptide
    MOTS-c
    Outcome
    Not applicableAntinociceptive effect with AMPK antagonist compound C
    Study

    mousen: not reported in source

    formalin test
    Comparator
    MOTS-c with compound C (10 mg/kg, i.p.)
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    50 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The antinociceptive effects of MOTS-c (50 mg/kg, i.p.) were attenuated by the AMPK antagonist compound C (10 mg/kg, i.p.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MOTS‑c 50 mg/kg reduced serum levels of pro-inflammatory cytokines.

    In plain wordsIn mice, MOTS‑c lowered blood levels of cytokines that promote inflammation.

    Peptide
    MOTS-c
    Outcome
    DecreasePro-inflammatory cytokine levels in serum
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    50 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c (50 mg/kg, i.p.) significantly reduced pro-inflammatory cytokine levels and elevated the level of anti-inflammatory cytokine in mouse serum.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MOTS‑c 50 mg/kg raised the serum level of an anti-inflammatory cytokine.

    In plain wordsIn mice, MOTS‑c raised the blood level of a cytokine that reduces inflammation.

    Peptide
    MOTS-c
    Outcome
    IncreaseAnti-inflammatory cytokine level in serum
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    50 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c (50 mg/kg, i.p.) significantly reduced pro-inflammatory cytokine levels and elevated the level of anti-inflammatory cytokine in mouse serum.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, MOTS‑c treatment increased AMPKα phosphorylation in the spinal cord.

    In plain wordsIn mice, MOTS‑c increased activation of the enzyme AMPK in the spinal cord.

    Peptide
    MOTS-c
    Outcome
    IncreaseAMPKα phosphorylation in spinal cord
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c treatment significantly increased AMPKα phosphorylation level
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, MOTS‑c treatment suppressed formalin-induced ERK activation in the spinal cord.

    In plain wordsIn mice, MOTS‑c reduced formalin-triggered activation of the ERK signal protein in the spinal cord.

    Peptide
    MOTS-c
    Outcome
    DecreaseERK activation in spinal cord
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    suppressed formalin-induced extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinases (JNK), and P38 activation
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, MOTS‑c treatment suppressed formalin-induced JNK activation in the spinal cord.

    In plain wordsIn mice, MOTS‑c reduced formalin-triggered activation of the JNK signal protein in the spinal cord.

    Peptide
    MOTS-c
    Outcome
    DecreaseJNK activation in spinal cord
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    suppressed formalin-induced extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinases (JNK), and P38 activation
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, MOTS‑c treatment suppressed formalin-induced P38 activation in the spinal cord.

    In plain wordsIn mice, MOTS‑c reduced formalin-triggered activation of the P38 signal protein in the spinal cord.

    Peptide
    MOTS-c
    Outcome
    DecreaseP38 activation in spinal cord
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    suppressed formalin-induced extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinases (JNK), and P38 activation
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice, MOTS‑c treatment suppressed formalin-induced c-fos expression in the spinal cord.

    In plain wordsIn mice, MOTS‑c reduced formalin-triggered c-fos activity, a marker of nerve cell activation, in the spinal cord.

    Peptide
    MOTS-c
    Outcome
    Decreasec-fos expression in spinal cord
    Study

    mousen: not reported in source

    formalin test
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    and c-fos expression in the mouse spinal cord.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.